These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 30334242

  • 1. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
    Weiss J, Afghahi A, Shagisultanova E, Diamond JR.
    Oncology (Williston Park); 2018 Oct 15; 32(10):513-5. PubMed ID: 30334242
    [No Abstract] [Full Text] [Related]

  • 2. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q, Lin X, Ye L, Xu R, Dai Y, Zhang Y, Chen Q.
    Target Oncol; 2019 Apr 15; 14(2):139-148. PubMed ID: 30941621
    [Abstract] [Full Text] [Related]

  • 3. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
    Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M, de Azambuja E.
    Eur J Clin Invest; 2021 Jul 15; 51(7):e13535. PubMed ID: 33662161
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D.
    Breast Cancer; 2018 Sep 15; 25(5):506-516. PubMed ID: 29700711
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ.
    Am J Health Syst Pharm; 2019 Aug 01; 76(16):1183-1202. PubMed ID: 31369120
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors.
    Sánchez-Bayona R, Oliveira M.
    Ann Oncol; 2024 Aug 01; 35(8):689-691. PubMed ID: 39048261
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.